UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Life Science

Using customer needs to drive Blockchain innovation

Manuela Maria Schöner, part of the Corporate Strategy & Consulting division at Boehringer Ingelheim, spoke to us recently about her work with blockchain. She described her perspective on the use of data in the industry, and how Blockchain could become a key tool in meeting the needs of the primary stakeholders: patients.

Read More

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.

Read More

How should healthcare stakeholders differentiate hype from reality with blockchain technology?

In my previous post, I discussed the likely applications of Blockchain technology in the short, medium, and long-term future. These applications follow on from the key strategic priorities necessitated by the healthcare industry’s trend towards digital decentralized care delivery models.

Read More

How do we build the solutions that will transform healthcare’s future?

We are building the solutions that will revolutionise healthcare in the future: solutions that will transform the trust relationship between the industry and patients, and the whole dynamic of healthcare. As co-founder of 23 Consulting, I am involved in supporting health organisations with their blockchain projects.

Read More

What Digital Pathology can learn from Radiology

Radiology is ahead of the curve because they’ve had CAD (Computer Aided Detection) for about 20 years. Radiology as a field has therefore had experience of introducing and integrating AI algorithms.

In my previous post, I talked about high-level cross imaging modalities. Here, I will discuss three challenges specific to pathology. I also work with Radiology imaging, and I think that comparisons between the two can help see how pathology might develop in the future.

Read More

A Finnish perspective on Blockchain adoption

The first topic I worked on that combined Blockchain and healthcare was the project I’m going to talk about at the Blockchain in Healthcare Congress. It was commissioned by the Finnish government, looking at how blockchain technology and Smart Contracts could help in a planned governmental social and healthcare reform. 

Read More

Inhibiting NOX enzymes to treat multiple diseases with high medical need

NOX enzymes are a family of enzymes which amplify multiple signaling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.

Read More

Four challenges in developing AI algorithms for medical imaging

Unsurprisingly, there is a lot of hype surrounding AI. Available deep learning packages make it so easy to create models and so we can expect lots of them to emerge. Anyone able to access sufficiently labelled data can start building models.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive